Les professionnels de GBNews.ch s'allient à la puissance des technologies en intelligence artificielle générative, pour informer la communauté des affaires et le grand public, des dernières tendances et des évolutions du marché de l'emploi.
In 2014, Quotient Limited settled in the business area of Eysins, near Geneva, and has since hired over 50 employees at this location. We recently met with members of Quotient’s Human Resources Department to better understand the company's development plan and the expertise they are seeking. By March 2016, the company aims to hire more than 85 employees at its Eysins manufacturing site in all departments, including Quality, Validation, Quality Control, Process Engineering, Maintenance/Engineering, Production, Regulatory Affairs and Corporate Support. The positions will be published on Quotient’s own website, as well as on Linkedin and Jobup.
The company and its activity
Quotient is an established, commercial-stage diagnostics company committed to reducing healthcare costs and improving patient care through the development and commercialization of innovative tests within established markets. The company's initial focus involves blood grouping and serological disease screening, which is commonly referred to as transfusion diagnostics. Blood grouping involves specific procedures performed at donor or patient testing laboratories to characterize blood, which includes antigen typing and antibody identification. Serological disease screening involves the screening of donor blood for unwanted pathogens.
Since the 1940’s, Quotient's original research & manufacturing subsidiary has traded under the name Alba Bioscience. This operation was established to manufacture blood tests for the Scottish National Blood Transfusion Service. Following its privatization in 2007, Alba Bioscience became the foundation of what is now Quotient. Today, Quotient has operations in Edinburgh, Scotland and Eysins, Switzerland, as well as offices Newtown, Pennsylvania and Chapel Hill, North Carolina within the United States. Alba Bioscience currently manufactures over 200 products, which are sold in over 30 countries. Quotient’s primary customers are independent hospitals, reference labs and donor testing labs, as well as original equipment manufacturing (OEM) customers.
MosaiQ™ and Eysins
Quotient is completing the development of MosaiQ™, a transformational technology platform ideally suited for both blood grouping and disease screening. MosaiQ™ will initially consist of two separate consumables, one for blood grouping and one for serological disease screening, as well as a high-throughput instrument. The consumables will be produced at the Eysins facility and shipped to customers around the world, while the instrument will be manufactured by an external partner.
“Our MosaiQ™ technology is advanced and exciting, which has required the development of a totally new manufacturing process. We are excited to work with the growing team in Eysins to bring this transformational technology to our customers,” commented Ed Farrell, President of Quotient Limited.
Transfusion medicine demands the highest standard of performance, quality and service. However, there has not been a major advancement in the automation of transfusion diagnostics within the past two decades. Consequently, complex and expensive manual testing procedures remain necessary in both donor and patient testing laboratories. Quotient’s novel approach incorporates existing, well-characterized tests for blood group antigens and antibodies on a single consumable for the global market. Quotient believes that, when launched, MosaiQ™ will be the only commercially-available automation platform capable of offering this breadth of testing on a single consumable, eliminating the need for routine manual testing. The company firmly believes that MosaiQ™ will significantly reduce the cost of blood grouping in both the donor and patient testing environments, while also improving global health outcomes through better and easier matching of donor and patient blood. MosaiQ™ has also been designed to perform all currently mandated serological disease screening tests, such as HIV and Hepatitis, while also enabling the low cost detection of additional pathogens, increasing the safety of the blood supply.
Sources:
Interview with the HR Department – Paul Stuart and Elisabeth Troussier
http://www.quotientbd.com/about-us